Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network. Long SA, et al. Among authors: aggarwal s. Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20. Diabetes. 2012. PMID: 22721971 Free PMC article. Clinical Trial.
Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, Boyle KD, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, McNamara J, Bluestone JA; AbATE Study Team. Herold KC, et al. Among authors: aggarwal s. Diabetes. 2013 Nov;62(11):3766-74. doi: 10.2337/db13-0345. Epub 2013 Jul 8. Diabetes. 2013. PMID: 23835333 Free PMC article. Clinical Trial.
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Rigby MR, et al. Among authors: aggarwal s. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23. Lancet Diabetes Endocrinol. 2013. PMID: 24622414 Free PMC article. Clinical Trial.
Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR; START Study Team. Gitelman SE, et al. Among authors: aggarwal s. Lancet Diabetes Endocrinol. 2013 Dec;1(4):306-16. doi: 10.1016/S2213-8587(13)70065-2. Epub 2013 Aug 28. Lancet Diabetes Endocrinol. 2013. PMID: 24622416 Free PMC article. Clinical Trial.
The 2024 generation.
Aggarwal SS, Andreani C, Deng Z, Frede J, Kameneva P, Kovatcheva M, Micevic G, Nicolson F, Puschhof J, Roberts M, Wang G, Watson DC. Aggarwal SS, et al. Nat Cancer. 2024 Dec;5(12):1774-1778. doi: 10.1038/s43018-024-00866-2. Nat Cancer. 2024. PMID: 39690227 No abstract available.
The role of very low-dose prophylaxis in severe hemophilia patients.
Aggarwal S, Tomar A, Kumar K, Kumar A, Kumar S, Garg S, Kumar N, Nandi S. Aggarwal S, et al. Indian J Pharmacol. 2024 Sep 1;56(5):312-316. doi: 10.4103/ijp.ijp_333_24. Epub 2024 Dec 16. Indian J Pharmacol. 2024. PMID: 39687953 Free article.
2,591 results